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Dr Duke E. Cameron (Baltimore, Md). I have no disclosures.
Dr Zhu, I congratulate you and your coauthors on this provoc-
ative and potentially groundbreaking study on the mechanism and
treatment of PVS. Your group has already made substantial contri-
butions to the characterization of this lesion, you have created a
powerful animal model, and now you have presented to us a novel
nonsurgical treatment.
Your present study suggests that TGF-b signaling might be
important to the venous intimal hyperplasia that characterizes
this lesion and that a strategy of angiotensin II blockade might
thwart the progressive myeloproliferation that occurs upstream
to the obstruction, similar to how the blockade can slow and
perhaps even prevent aneurysmal changes in the ascending aorta
in patients with Marfan syndrome.
I have 3 questions.
You pointed out in your report, although it was not presented
here, that when you measured the TGF-b levels in the banded
and losartan-treated piglets, they actually were not elevated in
the setting of banding, although you did see that in other models
of pulmonary artery banding that you had studied before. I am
curious to know whether you think this was a problem of perhaps
measuring TGF-b at the wrong location or the wrong time, or have
you actually revealed a new mechanism of losartan that could ac-
count for that finding? So, in other words, what are your thoughts
about how losartan is actually working?
My second question then is that losartan was given before the
pulmonary venous changes occurred, and I am interested to
knowwhether you are planning to use this model in a more chronic
phase to determine whether losartan truly prevents the changes or
has just delayed them and they did not appear within the first 8
weeks.
Of course, we would also like to know whether, if losartan is
given once the changes have already occurred, could it actually
reverse some of those changes, such as it appears to do in some
aneurysmal disease?diovascular Surgery c Volume 148, Number 6 2557
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DFinally, my last question, which I think everyone in the audi-
ence wants to know, is, have you given losartan to any of your clin-
ical patients? If so, to what group of patients and do you have any
findings to share with us?
Again, I congratulate you on a spectacular study.
Dr Zhu. Thank you very much, Dr Cameron, thanks for your
comments.
For your first question about the TGF-b discrepancy between
our present study and the previous study, we did show that TGF-
b was upregulated in our previous model. However, we did not
find that change in the present study. I think there are several rea-
sons. First, we used a slightly different model. In our previous an-
imal model, we banded all the pulmonary veins. However, in the
present study, we left the right middle pulmonary vein unbanded.
We intended to leave the right middle pulmonary vein unbanded to
improve survival and also to provide an intra-animal control. Thus,
the present model was less severe than the previous one. Actually
from the hemodynamic measurements, we found the mean pulmo-
nary arterial pressure in the present model to be slightly lower than
that in the previous model.
The second reason might have been related to specimen collec-
tion. In the present model, we collected the pulmonary vein sam-
ples much more distally than in the previous model, because we
wanted to focus on the upstream pulmonary vein.
Finally, I think, actually, for TGF-b, for its role in PVS develop-
ment, we are still not quite sure. More mechanism studies are
required, and our research group is investigating the underlying
mechanism now. TGF-b could be involved in the early phase;
for instance, perhaps it initiates the process of pulmonary vein ste-
nosis, but perhaps it is not required to maintain the PVS. Thus, we
might have missed the timing to detect when the TGF-b is
elevated. Therefore, I think will be good for us to evaluate the
TGF-b levels at different points in a chronic model.
That brings us to your second question. In the present study, we
gave losartan before the development of PVS.
We did not give losartan treatment for established PVS. From
our previous study, we had found that PVS starts at around 3
weeks after the banding procedure. We saw some flow turbu-
lence of the banded pulmonary veins on echocardiography.
Also, when we killed the pigs at 3 weeks after the operation,
we found some pathologic changes. Thus, I think in future
studies, we will start giving losartan 3 weeks after banding to
test the ability of losartan to reverse established disease. That
is our next step. I think it will be very interesting to proceed
with this experiment.2558 The Journal of Thoracic and Cardiovascular SurThe last question I think is the one all of us are mostly interested
in—whether we can bring losartan into clinical use. Currently, we
have not used losartan clinically; however, we are interested in do-
ing so because losartan is a widely used Food and Drug Administra-
tion-approvedmedication with a good safety profile, and the dosage
we used in the present study was within the normal clinical use.
We have not started the clinical trial for a few reasons. First, in
the present study, we used losartan before the PVSwas established,
which is not very similar to the most common clinical setting. The
translation of this model to a clinical study would likely entail pro-
phylactic use of losartan in every patient with total anomalous pul-
monary venous drainage at risk of PVS. However, we know that
the incidence of PVS after total anomalous pulmonary venous
drainage repair is only around 10%. So, if we wanted to detect
whether losartan has a beneficial prophylactic effect, we might
need a few hundred patients to have enough power to identify
the effects. In a single center, we would not have enough patients.
We would need a multiple center clinical trial to obtain enough
patients.
We could consider using losartan only in high-risk patients to
increase the likelihood of detecting a beneficial effect; however,
these patients are also still very few, and sometimes it is a bit diffi-
cult to predict which patients will develop PVS and which will not.
We are very interested in the use of losartan to treat established
PVS. I think before we can start the clinical trial of those patients,
we will still need some more supportive evidence from animal
studies, and this is also our next step.
Finally, for the potential clinical trial of this rare, but relentless,
pulmonary vein disease, we need multiple centers to enroll enough
patients, and all of you are welcome to join this study.
Dr John E. Mayer, Jr (Boston, Mass). It seems to me, unless I
missed something in your presentation, you have sort of a control,
namely, that right middle pulmonary vein that you did not band.
How were your findings different in that area compared with the
other areas in which the veins were banded?
Dr Zhu. Thank you, that is a very good question. Actually, we
left the right middle pulmonary vein unbanded. From our findings,
when we killed the pigs, morphologically, the right middle pulmo-
nary vein was dilated. It indicates pulmonary flow distribution to
the right middle pulmonary vein, which can decompress the heart.
We also performed pathologic tests, and we did not find the same
intimal hyperplasia in this unbanded pulmonary vein as was seen
in the banded veins. Possibly, a longer study duration might have
allowed us to detect histologic changes in the unbanded pulmonary
veins.gery c December 2014
